Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ESP-001,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Esperas Pharma
Deal Size : Undisclosed
Deal Type : Financing
Details : The funding will be used to conduct a proof-of-concept study in a genetically selected sub-population of high-grade serous ovarian cancer. Esperas is developing the first oral Check 1 inhibitor, ESP-001 with the potential to treat certain types of cancer...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 21, 2023
Lead Product(s) : ESP-001,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Esperas Pharma
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : RP-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Recurv Pharma
Deal Size : $24.0 million
Deal Type : Financing
Details : Recurv Pharma will use the funding in the development of a novel taxane therapy, RP-001, therapy to treat solid tumors. RP-001 is a new chemical entity (NCE) delivered in a nano-emulsion formulation that focuses the drug delivery to the tumor, sparing he...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : RP-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Recurv Pharma
Deal Size : $24.0 million
Deal Type : Financing
Contact Us!
Reset All
